OmniAb, Inc. (OABI)

OmniAb's share price has underperformed the S&P500 Index by -13.76% in the past six months, but shares were trading +12.11% higher than their 200-day moving average. The company has consistently reported losses and is expected to remain unprofitable for at least the next three years, despite a forecasted annual revenue increase of 30.4%. Key events impacting the stock price include the launch of OmniUltra, a new technology offering, a technology license and services agreement with an incubated company, Q3, Q2 and Q1 2025 financial results reporting losses and missing revenue estimates, a $30 million private placement, and a 10% pullback in stock price.

OmniAb experiences some demand seasonality, with the first quarter traditionally being its largest cash use quarter. The company's revenue streams are described as "lumpy" and partially outside its direct control due to its heavy reliance on partner-driven royalties and the timing of milestone events in drug development.

OmniAb, Inc. is a biotechnology company specializing in the discovery and development of therapeutic antibodies, operating within the biotechnology and medical research industry. Its core business involves licensing its proprietary discovery research technology to facilitate the discovery of next-generation therapeutics. The company's technology platform, Biological Intelligence™, utilizes proprietary and engineered transgenic animals to create and screen diverse antibody repertoires. Major products and technologies include various transgenic animal platforms and OmniDeep™, a suite of in silico, artificial intelligence (AI), and machine learning tools. The company provides both fee-for-service collaborations and license agreements.

OmniAb, Inc. has a global reach, licensing its discovery research technology to partners in the United States, Europe, Japan, China, and Canada. The company maintains research facilities in North America and Europe. Its corporate headquarters and primary research and development facilities are located in Emeryville, California, with additional research and development spaces in Durham, North Carolina, and Tucson, Arizona.

OmniAb has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.50. The average stock forecast for OABI in the next 12 months is $7.48, representing a potential upside of 283.59%. However, the company faces challenges including persistent unprofitability and cash burn, reliance on partner drug approvals, regulatory pressures, and shareholder dilution.

Institutional investors hold a significant stake in OmniAb, Inc., with 72.08% of the stock held by institutions. The top 13 shareholders collectively own 51% of the company. Major institutional owners include Avista Capital Holdings LP, Whitefort Capital Management, LP, Ash X LP, BlackRock Advisors LLC and Vanguard Fiduciary Trust Co. Individual insiders hold 8.60% of the stock. In the past three months, OmniAb insiders have bought more shares than they have sold, with purchases totaling $107,707.00 and sales at $89,439.00. Notable insider purchases include Matthew Foehr (CEO), John Higgins (Chairman of the Board), Jennifer Cochran (Member of the Board), and Steven Love (Member of the Board).